Benefits of Using CART-T Therapies to Treat Rare Cancers
Manuel Litchman, MD, President and CEO of Mustang Bio Inc, highlights the advantages of using CAR-T therapies as treatments for rare cancers.
Alectinib Outpaces Crizotinib In Treatment of ALK+ NSCLC Patients in Phase 3 ALEX Trial
Researchers release updated data from the phase 3 ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell lung cancer.
How A Team-Based Approach Works For Treatment of Brain Tumors
Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, explains what a team approach should look like when treating brain tumors and other rare cancers.
PET Scans Help Providers Tailor Therapy for Esophageal Cancer Patients, Increasing Survival
Researchers find that the use of PET scans at baseline and after induction therapy can help them tailor chemotherapy regimens in esophageal cancer patients, increasing survival.
Sharing Experiences: The Most Valuable Resource in Rare Diseases
Owen A. O’Connor, MD, PhD, Director of Center for Lymphoid Malignancies at Columbia University, emphasizes the importance of sharing experiences among physicians and researchers in the rare diseases like peripheral T-cell lymphomas.
Team Approaches with Brain Tumors and Other Rare Cancers
Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, discusses the importance of team approaches when treating brain tumors and other rare cancers.
Phase 1 Trial of Ivosidenib for Patients with AML Boasts Positive Results
Researchers report positive results for phase 1 trial of ivosidenib in patients with IDH1+ acute myeloid leukemia.
Treatment at Specialized Cancer Center Linked with Improved Survival in Children with ALL
Results of a recent study demonstrate that treatment at a specialized cancer center is associated with better leukemia-specific survival in children, adolescents, and young adults.
New Treatment Regimens Boost Survival Rates in Children with T-ALL or T-LL
A new phase 3 clinical trial boasts highest survival rates of these T-cell malignancies.
Peptide Vaccine Demonstrates Safety & Immunogenicity in Patients with Astrocytomas
First-in-man phase 1 trial meets its primary endpoints by demonstrating safety and immunogenicity of a mutation-specific IDH1R132H peptide vaccine.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.